KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guerin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)

被引：2
|
作者：
Shariat, S. F. [1 ]
Steinberg, G. [2 ]
Kamat, A. M. [3 ]
Shore, N. D. [4 ]
Alanee, S. [5 ,6 ]
Nishiyama, H. [7 ]
Nam, K. [8 ]
Godwin, J. L. [8 ]
Kapadia, E. [8 ]
Hahn, N. [9 ]
机构：
[1] Med Univ Vienna, Urol, Vienna, Austria
[2] NYU Langone Hlth, Urol, New York, NY USA
[3] Univ Texas MD Anderson Canc Ctr, Urol, Houston, TX 77030 USA
[4] Carolina Urol Res Ctr, Urol, Myrtle Beach, SC USA
[5] Michigan State Univ, Urol, Detroit, MI USA
[6] Michigan State Univ, Detroit Med Ctr, Detroit, MI USA
[7] Univ Tsukuba, Urol, Tsukuba, Ibaraki, Japan
[8] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[9] Johns Hopkins Univ, Sch Med, Med Oncol, Baltimore, MD USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
718TiP
引用
收藏
页码：S723 / S723
页数：1
相关论文
共 50 条
  • [31] Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)
    de Wit, R.
    Kulkarni, G. S.
    Uchio, E.
    Boormans, J. L.
    Roumiguie, M.
    Krieger, L. E. M.
    Singer, E. A.
    Bajorin, D. F.
    Kamat, A. M.
    Grivas, P.
    Seo, H. K.
    Nishiyama, H.
    Konety, B. R.
    Saretsky, T.
    Li, H.
    Nam, K.
    Sbar, E.
    Balar, A. V.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [32] Single instillation of mitomycin C plus bacillus Calmette-Guerin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer
    Weiss, Brian E.
    Pietzak, Eugene J.
    Wein, Alan J.
    Malkowicz, S. Bruce
    Guzzo, Thomas J.
    [J]. CANADIAN JOURNAL OF UROLOGY, 2015, 22 (04) : 7876 - 7881
  • [33] The challenges of Bacillus of Calmette-Guerin (BCG) therapy for high risk non muscle invasive bladder cancer treatment in older patients
    Racioppi, Marco
    Di Gianfrancesco, Luca
    Ragonese, Mauro
    Palermo, Giuseppe
    Sacco, Emilio
    Bassi, PierFrancesco
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2018, 9 (05) : 507 - 512
  • [34] PHASE 2 KEYNOTE-057 STUDY: PEMBROLIZUMAB FOR PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN
    Kulkarini, Girish S.
    de Wit, Ronald
    Balar, Arjun V.
    Kamat, Ashish
    Uchio, Edward
    Mourey, Loic
    Krieger, Laurence
    Singer, Eric A.
    Bajorin, Dean
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuku
    Konety, Badarinath
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara
    Boormans, Joost L.
    [J]. JOURNAL OF UROLOGY, 2019, 201 (04): : E616 - E616
  • [35] A phase 3, randomized, open-label, multicenter, global study of Durvalumab and bacillus calmette-Guerin (BCG) vs BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC)
    Boegemann, M.
    Abdrashitov, R.
    Casuscelli, J.
    Feyerabend, S.
    Hatiboglu, G.
    Hegele, A.
    Hellmis, E.
    Klier, J.
    von Klot, C.
    Schmitz-Draeger, B.
    Spiegelhalder, P.
    Stagge, E.
    De Santis, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 105 - 105
  • [36] A phase Ill, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guerin (BCG) versus BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC).
    De Santis, Maria
    Abdrashitov, Ramil
    Hegele, Axel
    Kolb, Margaret
    Parker, Suzanne
    Redorta, Juan Palou
    Nishiyama, Hiroyuki
    Xiao, Feng
    Gupta, Ashok Kumar
    Shore, Neal D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [37] Sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guerin for the treatment of high-risk, treatment-naive, non-muscle invasive bladder cancer.
    McElree, Ian M.
    Steinberg, Ryan L.
    Mott, Sarah L.
    O'Donnell, Michael A.
    Packiam, Vignesh T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [38] Re: The Challenges of bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients
    Chang, Sam S.
    [J]. JOURNAL OF UROLOGY, 2020, 203 (06): : 1061 - 1061
  • [39] Re: The Challenges of bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients
    Griebling, Tomas L.
    [J]. JOURNAL OF UROLOGY, 2019, 201 (05): : 836 - 836
  • [40] Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)-unresponsive high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C.
    Kulkarni, Girish S.
    Gupta, Shilpa
    Necchi, Andrea
    Shore, Neal D.
    Dave, Hema Kishore
    Kapadia, Ekta
    Zhao, Qing
    Kamat, Ashish M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS719 - TPS719
12345